Biofrontera

Biofrontera FCF Growth

The Year-over-Year Free Cash Flow Growth of Biofrontera (B8FK.DE) as of Nov 21, 2026 is -61.91 %. In the previous year, Year-over-Year Free Cash Flow Growth was 2.83 % — a change of -2,289.41% (lower).

FCF Growth

-61.91 %

YoY

-2,289.41%

Last updated:

Year-over-Year Free Cash Flow Growth of Biofrontera is 2025 -61.91 % . Year-over-Year Free Cash Flow Growth of Biofrontera was 2024 2.83 % . It decreases by -2,289.41% lower compared to the previous year.

The Biofrontera FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
-3.19 EUR
Jan 1, 2019
-149.14 EUR
Jan 1, 2020
89.57 EUR
Jan 1, 2021
922.80 EUR
Jan 1, 2022
-116.36 EUR
Jan 1, 2023
41.98 EUR
Jan 1, 2024
2.83 EUR
Jan 1, 2025
-61.91 EUR
The Biofrontera FCF Growth history
YEARFCF GrowthYoY
-61.91 %-2,289.41%
2.83 %-93.26%
41.98 %-136.08%
-116.36 %-112.61%
922.80 %+930.21%
89.57 %-160.06%
-149.14 %+4,577.07%
-3.19 %-84.38%
-20.42 %+52.35%
-13.40 %-39.93%
-22.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

Year-over-Year Free Cash Flow Growth of Biofrontera is -61.91 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Biofrontera since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Biofrontera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Biofrontera

All Key Metrics — Biofrontera